HER2 t-haNK(ImmunityBio)

N/A

Report date: 2022/09/06 18:03:22

Base Information

Drug NameHER2 t-haNK(ImmunityBio)

Drug Alias NameHER-2-t-haNK

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacements

TargetsNot applicable

Therapy Area/IndicationsStomach NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNantkwest Inc Immunitybio Inc

China Registration ClassN/A

Develop Information

Active CompaniesNantkwest Inc

Inactive CompaniesN/A

Active IndicationsStomach NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A